Skip to content

Verrica Pharmaceuticals Inc.

VRCA

CIK 0001660334

← back to feed
Revenue (TTM)
$19.54M
+47.7% YoY Q1 May 2026
Net Income (TTM)
−$19.49M
+76.6% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.49
+88.6% YoY Q1 May 2026
Gross Margin
87.2%
Q1 May 2026
Operating Margin
-75.3%
Q1 May 2026
Net Margin
-99.8%
Q1 May 2026
Free Cash Flow (TTM)
−$46.7M
Q1 May 2026
Cash
$20.6M
Q1 May 2026
Total Debt
$0
Q1 May 2026
Shares Outstanding
17.18M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings